贝达药业：项目如有重大进展 会及时履行信息披露义务

Core Viewpoint - The company, Betta Pharmaceuticals, is advancing two innovative drug candidates aimed at treating specific types of cancer, with a commitment to timely information disclosure regarding significant developments [1]. Group 1: Drug Development - The self-developed BPI-520105 tablets are a new, highly selective pan-EGFR small molecule inhibitor targeting patients with solid tumors carrying epidermal growth factor receptor (EGFR) mutations [1]. - The BPI-572270 capsules are a novel, potent pan-RAS "non-degradable molecular glue" inhibitor intended for the treatment of patients with advanced malignant solid tumors [1]. - Both projects are progressing in accordance with clinical research plans [1].